Clinical trials: Hematological Patients
Hematological Malignancies
Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
The goal of this prospective study is to assess the overall mortality (whether related to relapse/progression or toxicity - TRM-) at one year after allogeneic stem cell transplantation prepared by a so-called reduced-toxicity…
- Trial name
- ITT 08-01 (NCT00841724)
- Testing
- Fludarabine, Busulfan, Thymoglobuline
- Where
- 3 sites in France
- Volunteers
- 82 people
- Sponsor
- Nantes University Hospital
Hematological Malignancies
M-2018-334 in Hematological Malignancies
This is a single-center, open-label, single-arm, pilot clinical study using TCRα/β and CD45RA depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.
- Trial name
- HAPLO2022 (NCT06225050)
- Testing
- CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Miltenyi Biomedicine GmbH
Blood Cancers, Leukemia
A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece
This clinical trial aims to determine whether a manualised group intervention for people with blood cancers can help them experience positive psychological changes following their diagnosis, known as post-traumatic growth.
- Conditions
- Blood Cancers, Leukemia, Lymphoma, Bone Marrow Transplant
- Trial name
- NCT07814170
- Testing
- A manualised post-traumatic growth intervention for people with hematological cancers
- Where
- 2 sites in Greece
- Volunteers
- 80 people
- Sponsor
- University of West Attica
Hematological Malignancies
A Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematological Malignancies
Primary Objective: To evaluate the safety, tolerability, and dose-limiting toxicity of CD70-targeted chimeric antigen receptor allogeneic T-cell injection (CHT101) in the treatment of subjects with CD70-positive…
- Trial name
- NCT07809126
- Testing
- CD70-targeted chimeric antigen receptor allogeneic T-cell injection (CHT101)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing Miracle Biotechnology Co., Ltd.
Hematological Malignancies
A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies
Primary Objective: To evaluate the safety, tolerability, and dose-limiting toxicity of anti-CD70 chimeric antigen receptor allogeneic T-cell injection (CHT101) in the treatment of CD70-positive relapsed/refractory T-cell and…
- Trial name
- NCT07809139
- Testing
- CHT101
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing Miracle Biotechnology Co., Ltd.
Cancer, Lung Cancer
Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
Optimal patient-centered care is often not being delivered to cancer patients, especially to vulnerable populations like those living in underserved rural areas.
- Conditions
- Cancer, Lung Cancer, Colorectal Cancer, Hematological Cancer
- Trial name
- PRISMA (NCT07788729)
- Testing
- PRISMA-interventions
- Where
- 8 sites in Germany
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- University of Regensburg
Cancer (Solid Tumors), Cancer and / or Hematological Malignancy
Comparative Effectiveness of Verbal Instruction Versus Simulation Video Education Among Cancer Patients Undergoing Radiation Therapy
The goal of this Randomized Controlled Trial is to compare the effectiveness of radiotherapy-specific, physician-led educational videos introduced before the initial Radiation Therapy consultation .
- Trial name
- CARE-RT (NCT07367997)
- Testing
- Radiotherapy-Specific Educational Video
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
- Trial name
- NCT07220616
- Testing
- DS3790a, Combination drug
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 420 people
- Sponsor
- Daiichi Sankyo
Hematological Malignancy
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
To determine the safety, efficacy and optimal cell dose of CAR 5/IL15-transduced CB-NK cells in patients with relapsed/refractory T-cell malignances, mantle cell lymphoma, and chronic lymphocytic leukemia.
- Trial name
- NCT05110742
- Testing
- Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Hematological Malignancies
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
To determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.
- Trial name
- NCT07137481
- Testing
- C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Hematological Malignancies, Invasive Fungal Disease
mNGS for IFD in Patients With Hematological Malignancies
Invasive fungal disease (IFD) refers to an infectious disease caused by fungi invading the human body, growing and reproducing in tissues, organs, or blood, and leading to inflammatory responses and tissue damage.
- Trial name
- NCT07763184
- Testing
- metagenomic next-generation sequencing
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hematological Malignancies
Dose-range Finding Treosulfan-based Conditioning
Evaluation of the safety and efficacy of 3 x 10, 3 x 12 or 3 x 14 g/m² Treosulfan resp., combined with 5 x 30 mg/m² fludarabine prior to allogeneic, hematopoietic stem cell transplantation of patients with hematological…
- Trial name
- NCT01063647
- Testing
- Treosulfan
- Where
- 7 sites in Finland, Germany and 2 more
- Volunteers
- 56 people
- Sponsor
- medac GmbH
Relapsed or Refractory Multiple Myeloma, Hematological Malignancy
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
This is a Phase 1a/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG301 in Patients with Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- Trial name
- NCT04684108
- Testing
- SG301
- Where
- 14 sites in China
- Volunteers
- 61 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Hematological Malignancies
Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies
The goal of this clinical research study is to learn about the effects of weighted blankets on sleep quality in patients with blood cancers. Weighted blankets are heavier blankets that contain inner weight beads.
- Trial name
- NCT06584955
- Testing
- Weighted Blanket
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Hematological Malignancies
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
- Trial name
- MajesTEC-1 (NCT04557098)
- Testing
- Teclistamab
- Where
- 51 sites in United States, Belgium and 9 more
- Volunteers
- 194 people
- Sponsor
- Janssen Research & Development, LLC
Oral Mucositis, Total Body Irradiation
Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant
The goal of this phase II, single-arm interventional clinical trial is to evaluate whether oral sodium copper chlorophyllin (CHL) can reduce the frequency and severity of oral mucositis in patients aged 12-65 years undergoing…
- Conditions
- Oral Mucositis, Total Body Irradiation, Hematological Malignancies, Hematopoietic Stem Cell Transplantation (HSCT)
- Trial name
- ChROMME-TBI (NCT07709195)
- Testing
- Sodium Copper Chlorophyllin
- Where
- India
- Volunteers
- 17 people
- Sponsor
- Tata Memorial Centre
Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease
Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients
What is acute Graft versus host disease (aGvHD)? GvHD is a complication that can occur after an allogeneic stem cell transplant resulting in damage to some organs. The death rate of GvHD patients is 15-40%.
- Conditions
- Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease, Hematological Malignancy
- Trial name
- NCT07724873
- Testing
- SWA (standardized root extract of Withania somnifera)
- Where
- 2 sites in India
- Volunteers
- 54 people
- Sponsor
- Tata Memorial Centre
Cancer, Anticancer Treatment
Risk Prediction Scores for Cardiotoxicity in Cancer Patients Treated With Cardiotoxic Anticancer Therapies in Europe
Cancer management has undergone major advances over the past 30 years. Several anticancer therapies are now highly effective, allowing many cancers to become chronic diseases through sequential lines of treatment.
- Conditions
- Cancer, Anticancer Treatment, Cardiovascular Disease Risk Factor, Cardiovascular Diseases
- Trial name
- EUCARTOXSCORES (NCT07621289)
- Testing
- antineoplastic agents, endocrine therapy, immunostimulants drugs (ATC classification)
- Volunteers
- 10,000 people
- Sponsor
- University Hospital, Caen
Haploidentical Hematopoietic Stem Cell Transplant, Hematological Malignancies
To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers
Cyclophosphamide is the name of a medicine given to prevent graft-versus-host-disease (GVHD) after half-matched transplant. This medicine is given on the 3rd and 4th day after stem cell transplant.
- Trial name
- NCT07719946
- Testing
- Cyclophosphamide
- Where
- 2 sites in India
- Volunteers
- 20 people
- Sponsor
- Tata Memorial Centre
Hematological Malignancy, GVHD - Graft-Versus-Host Disease
Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease.
Study Design Prospective, single center, single arm, Phase II study. Research aims and objectives Aim: To evaluate the efficacy and safety of standardized Withaferin A in steroid refractory acute GvHD in patients post allogeneic…
- Conditions
- Hematological Malignancy, GVHD - Graft-Versus-Host Disease, Steriod Refractory
- Trial name
- Withaferin_A (NCT07708987)
- Testing
- Standardized Withaferin A (SWA)
- Where
- India
- Volunteers
- 34 people
- Sponsor
- Tata Memorial Centre